Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
Adaptive Biotechnologies announced plans to separate its Minimal Residual Disease (MRD) diagnostics business from its Immune Medicine discovery platform. The company expects to identify a preferred path for the separation by year-end 2026, aiming to unlock value for both distinct business models.
Key figures
- Mrd emr accounts
- 175
- Mrd revenue 2023
- 103000000
- Mrd revenue 2025
- 212000000
- Mrd active trials
- 180
- Mrd covered lives
- 300000000
- Immune medicine patients
- 10000
- Mrd adjusted ebitda 2025
- 15000000
- Immune medicine tcr pairs
- 6000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.